

Receipt date: 09/27/2004

10785446 - GAU: 1614

SHEET 1 OF 4

| | | | |
|---|--|----------------------------------|-------------------------------|
| FORM PTO-1449 | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | ATTY. DOCKET NO. NOCAR.007A | APPLICATION NO. 10/785,446 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY) | | APPLICANT Otsuki et al. | |
| | | FILING DATE February 23, 2004 | GROUP 1614 |



U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE (IF APPROPRIATE) |
|---------------------|----|-----------------|----------|---------------------|-------|----------|---------------------------------|
| | 1 | 5,290,782 | 03/01/94 | Suzuki et al. | | | |
| | 2 | 5,395,836 | 03/07/95 | Shimada et al. | | | |
| | 3 | 5,446,046 | 08/29/95 | Belardinelli et al. | | | |
| | 4 | 5,532,368 | 07/02/96 | Kufner-Muhl et al. | | | |
| | 5 | 5,599,817 | 02/04/97 | Adamus et al. | | | |
| | 6 | 5,631,260 | 05/20/97 | Belardinelli et al. | | | |
| | 7 | 5,641,784 | 06/24/97 | Kufner-Mühl et al. | | | |
| | 8 | 5,668,139 | 09/16/97 | Belardinelli et al. | | | |
| | 9 | 5,688,802 | 11/18/97 | Kufner-Muhl et al. | | | |
| | 10 | 5,696,124 | 12/09/97 | Kufner-Muhl et al. | | | |
| | 11 | 6,187,780 | 02/13/01 | Blech et al. | | | |
| | 12 | 6,210,687 | 04/03/01 | Hosokawa et al. | | | |
| | 13 | US 2002/0115687 | 08/22/02 | Beckman et al. | | | |
| | 14 | 10/785,446 | 02/23/04 | Otsuki et al. | | | |

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
|---------------------|----|-----------------|----------|---------|-------|----------|-------------|----|
| | | | | | | | YES | NO |
| | 15 | WO 01/34604 | 05/17/01 | PCT | | | | |
| | 16 | WO 99/55339 | 11/04/99 | PCT | | | | |
| | 17 | WO 99/54331 | 10/28/99 | PCT | | | | |
| | 18 | WO 94/03456 | 02/17/94 | PCT | | | | |

| EXAMINER INITIAL | OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.) | |
|---------------------|--|---|
| | 19 | Aki et al.; "Effects of KW-3902, a Selective and Potent Adenosine A1 Receptor Antagonist, on Renal Hemodynamics and Urine Formation in Anesthetized Dogs," <i>Pharmacology</i> . (1997); 55:193-201 |
| | 20 | Barrett Richard J., "Realizing the Potential of Adenosine-Receptor-Based Therapeutics," <i>Proc. West. Pharmacol. Soc.</i> (1996);39:61-66 |

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LAR/ (04/09/2009)

| | | |
|--|--------------------------------|-----------------|
| EXAMINER | /Leslie A. Royds/ (04/09/2009) | DATE CONSIDERED |
| *EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT. | | |

| | | |
|---|----------------------------------|-------------------------------|
| FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY) | ATTY. DOCKET NO. NOCAR.007A | APPLICATION NO. 10/785,446 |
| | APPLICANT Otsuki et al. | |
| | FILING DATE February 23, 2004 | GROUP 1614 |

| EXAMINER INITIAL | OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.) |
|---------------------|--|
| 21 | Belardinelli et al.; "1,3 Dipropyl-8-[2-(5,6-Epoxy)Norbornyl]Xanthine, a Potent Specific and Selective A ₁ Adenosine Receptor Antagonist in the Guinea Pig Heart and Brain and in DDT ₁ MF-2 Cells," <i>Journal of Pharmacology and Experimental Therapeutics</i> . (1995); 275(3):1167-1176 |
| 22 | Bertolet et al.; "Differential antagonism of cardiac actions of adenosine by theophylline," <i>Cardiovascular Research</i> . (1996);32:839-845 |
| 23 | Broadley, Kenneth J.; "Drugs modulating adenosine receptors as potential therapeutic agents for cardiovascular diseases," <i>Exp. Opin. Ther. Patents</i> . (2000); 10(11):1669-1692 |
| 24 | Conlon et al.; "Effect of Intravenous Furosemide on Serum Theophylline Concentration," <i>Am. J. Hosp. Pharm.</i> (1981);38:1345-7 |
| 25 | Deckert et al.; "Adenosine A ₁ receptors in human hippocampus: inhibition of [³ H]8-cyclopentyl-1,3-dipropylxanthine binding by antagonist drugs," <i>Neuroscience Letters</i> . (1993);150:191-194 |
| 26 | Daghfous et al.; "Fasting in Ramadan, the asthmatics and sustained-release theophylline," <i>Annals of Saudi Medicine</i> . (1994) |
| 27 | Gellai et al.; "CVT-124, a novel adenosine A ₁ receptor antagonist with unique diuretic activity," <i>J. Pharmacol. Exp. Ther.</i> (1998);286(3):1191-6 |
| 28 | Giacoaia et al.; "Diuretics, Hypochloremia, and Outcome in Bronchopulmonary Dysplasia Patients," <i>Dev. Pharmacol. Ther.</i> (1991);4:212-220 |
| 29 | Gottlieb, Stephen S.; "Renal Effects of Adenosine A ₁ -Receptor Antagonists in Congestive Heart Failure," <i>Drugs</i> . (2001); 61(10):1387-1393 |
| 30 | Gottlieb et al.; "BG9719 (CVT-124), an Adenosine A ₁ Receptor Antagonist, Protects Against the Decline in Renal Function Observed with Diuretic Therapy," <i>Circulation</i> . (2002); 105(11):1348-1353 |
| 31 | Gottlieb et al.; "BG9719 (CVT-124), an A ₁ -Adenosine Receptor Antagonist, Preserves Glomerular Filtration Rate and is an Active Natriuretic in Congestive Heart Failure Patients," <i>Circulation</i> . (1998); 98(17):105 |
| 32 | Gottlieb et al.; "Effects of BG9719 (CVT-124), an A ₁ -adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure," <i>J. Am. Coll. Cardiol.</i> (2000);35(1):56-9 |
| 33 | Greenberg et al.; "An Oral Adenosine Antagonist, Preserves Renal Function, Improves Sodium Excretion and is Well Tolerated in Heart Failure Patients," <i>AHA Meeting Orlando, Florida. Poster/Abstract</i> (2003) |
| 34 | Ireland et al.; "FK-352 Adenosine A ₁ Antagonist Diuretic Antihypertensive," <i>Drugs of the Future</i> . (1997); 22(4):350-352 |
| 35 | Jackson, Edwin K.; "A ₁ receptor antagonists as diuretic/natriuretic agents," <i>Drugs of the Future</i> . (2002) |
| 36 | Jackson et al.; "A ₁ Receptor Blockade Induces Natriuresis with a Favorable Renal Hemodynamic Profile in SHHF/Mcc-fa(cp) Rats Chronically Treated with Salt and Furosemide," <i>Journal of Pharmacology and Experimental Therapeutics</i> . (2001); 299(3):978-987 |
| 37 | Kobayashi et al.; "Diuretic Effects of KW-3902 (8-(Noradamantan-3-yl)-1,3-dipropylxanthine), a Novel Adenosine A ₁ Receptor Antagonist, in Conscious Dogs," <i>Biol. Pharm. Bull.</i> (1993); 16(12):1231-1235 |
| 38 | Lasser, Richard P. "The Treatment of Heart Failure in the 'Intractable' (Refractory) Phase," <i>Advances in Cardiopulmonary Diseases Volume III</i> . Banyai et al. Ed. (1966);3:296-304 |
| 39 | Lucas et al.; "Novel Effects of Selective Adenosine Subtype 1(A ₁) Receptor Inhibition on Renal and Pulmonary Function in Heart Failure," <i>Surgical Forum</i> . (2001); 52:95-97 |
| 40 | Lucas et al. "Effects of Adenosine Receptor Subtype A ₁ on Ventricular and Renal Function," <i>Journal of Cardiovascular Pharmacology</i> . (2003); 38(4):618-624 |

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LAR/ (04/09/2009)

| | |
|--|-----------------|
| EXAMINER /Leslie A. Royds/ (04/09/2009) | DATE CONSIDERED |
| *EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT. | |

| | | |
|--|----------------------------------|-------------------------------|
| FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY) | ATTY. DOCKET NO. NOCAR.007A | APPLICATION NO. 10/785,446 |
| | APPLICANT Otsuki et al. | |
| | FILING DATE February 23, 2004 | GROUP 1614 |

| EXAMINER INITIAL | OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.) | |
|---------------------|--|--|
| | 41 | Lucas et al., "Cardiorenal Effects of Adenosine Subtype 1(A ₁) Receptor Inhibition in an Experimental Model of Heart Failure," <i>J. American College of Surgeons</i> : (2002); 194(5):603-609 |
| | 42 | Macolić et al., "Pharmacokinetics and interactions of digoxin theophylline and furosemide in diseases with edema," <i>International Journal of Clinical Pharmacology, Therapy and Toxicology</i> (1993);31(1):6-11 |
| | 43 | Mazkereth et al., "Effects of theophylline on renal function in premature infants," <i>American Journal of Perinatology</i> (1997);14(1):45-49 |
| | 44 | Merzon et al., "Effect of euphylline and lasix on the urea-excretion function of the kidneys in cardiac insufficiency," <i>Sov. Med.</i> (1971);34(5):119-24 |
| | 45 | Oberbauer et al., "Natriuretic effect of adenosine A ₁ -receptor blockade in rats," <i>Nephrology, Dialysis, Transplantation</i> . (1998);13(4):900-3 |
| | 46 | Patterson et al., "Selective A ₁ Adenosine Receptor Antagonism Improves Renal Function in Heart Failure," <i>Circulation</i> . (2000); 102(18):158 |
| | 47 | Pfister et al., "Synthesis and Biological Evaluation of the Enantiomers of the Potent and Selective A ₁ -Adenosine Antagonist 1,3-Dipropyl-8-[2-(5,6-epoxynorbonyl)]-xanthine," <i>J. Med. Chem.</i> (1997); 40(12):1773-1778 |
| | 48 | Pietrak A., "Intensive treatment of postoperative acute renal failure using furosemide and euphantine," <i>Pol. Przegl. Chir.</i> (1977);49(10A):1051-3 |
| | 49 | Schnackenberg et al., "An orally active adenosine A ₁ receptor antagonist, FK838, increases renal excretion and maintains glomerular filtration rate in furosemide-resistant rats," <i>British Journal of Pharmacology</i> . (2003); 139(8):1383-1388 |
| | 50 | Suzuki et al., "Adenosine A ₁ Antagonists. 2 Structure-Activity Relationships on Diuretic Activities and Protective Effects against Acute Renal Failure," <i>J. Med. Chem.</i> (1992); 35(16):3066-3075 |
| | 51 | Terai et al., "General pharmacology of the new non-xanthine adenosine A ₁ receptor antagonist (+)-(R)-[(E)-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)acryloyl]-2-piperidine ethanol," <i>Arzneimittelforschung</i> . (1996);46(2):185-91 |
| | 52 | Ticho et al., "Renal Effects of BG9928, an A ₁ Adenosine Receptor Antagonist, in Rats and Nonhuman Primates," <i>Drug Dev. Res.</i> (2003);58:486-492 |
| | 53 | Tongia et al., "Infraadditive diuretic efficacy of concurrent aminophylline and frusemide," <i>Indian J. Physiol. Pharmacol.</i> (1993);37(3):244-246 |
| | 54 | Watson et al., "Preferences of veterinarians for drugs to treat heart disease in dogs and cats," <i>Aust. Vet. J.</i> 72:401-403 (1995) |
| | 55 | Welch, William J., "Adenosine type 1 receptor antagonists in fluid retaining disorders," <i>Expert Opin. Investig. Drugs</i> . (2002); 11(11):1553-1562 |
| | 56 | Wilcox et al., "Natriuretic and Diuretic Actions of a Highly Selective Adenosine A ₁ Receptor Antagonist," <i>Journal of the American Society of Nephrology</i> , (1999); 10(4):714-720 |
| | 57 | Wilcox et al., "Adenosine A ₁ receptor antagonists: A new class of diuretic with blockade of proximal reabsorption and tubuloglomerular feedback," <i>Wiener Klinische Wochenschrift</i> . (1997); 109(12-13):532 |
| | 58 | Wolff et al., "CVT-124, a Novel and Selective A ₁ -Adenosine Antagonist, is a Diuretic in Man with both Proximal and Distal Tubular Sites of Action," <i>Circulation</i> . (1996); 94(8):95 |
| | 59 | Wolff et al., "Renal Effects of BG9719, a Specific A ₁ Adenosine Receptor Antagonist, in Congestive Heart Failure," <i>Drug Development Research</i> . (1998); 45:166-171 |
| | 60 | Yao et al., "The selective adenosine A ₁ receptor antagonist KW-3902 prevents radiocontrast media-induced nephropathy in rats with chronic nitric oxide deficiency," <i>European Journal of Pharmacology</i> . (2001); 414:99-104 |
| | 61 | Yao et al., "Effect of the selective adenosine A ₁ -receptor antagonist KW-3902 on lipopolysaccharide-induced reductions in urine volume and renal blood flow in anesthetized dogs," <i>Jpn. J. Pharmacol.</i> (2000); 84(3):310-5 |

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LAR/ (04/09/2009)

| | |
|--|-----------------|
| EXAMINER /Leslie A. Royds/ (04/09/2009) | DATE CONSIDERED |
| *EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT. | |

Receipt date: 09/27/2004

10785446 - GAU: 1614

SHEET 4 OF 4

| | | |
|--|----------------------------------|-------------------------------|
| FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY) | ATTY. DOCKET NO. NOCAR.007A | APPLICATION NO. 10/785,446 |
| | APPLICANT Otsuki et al. | |
| | FILING DATE February 23, 2004 | GROUP 1614 |

| | | |
|---------------------|--|--|
| EXAMINER INITIAL | OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.) | |
| | 62 | Zanardo et al., "Methylxanthines Increase Renal Calcium Excretion in Preterm Infants," <i>Biol. Neonate.</i> (1995);68:169-174 |

S:\DOCS\SKT\SKT-5488.DOC: 092404

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LAR/ (04/09/2009)

| | | |
|--|--------------------------------|-----------------|
| EXAMINER | /Leslie A. Royds/ (04/09/2009) | DATE CONSIDERED |
| *EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT. | | |